We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Flouting Court On Orphan Drug Exclusivity, Suit Says

Law360, New York (April 28, 2016, 7:57 PM EDT) -- The U.S. Food and Drug Administration is flouting a recent court ruling and federal law by refusing to grant orphan drug exclusivity for chemotherapy infusion Bendeka, according to a complaint filed Wednesday in D.C. federal court.

The suit filed by Bendeka developer Eagle Pharmaceuticals Inc. concerns a recently approved bendamustine drug that is promoted in the U.S. by Teva Pharmaceutical Industries Ltd. and intended to replace another bendamustine drug, Treanda, that is promoted by Teva and suddenly facing generic competition.

According to Eagle, the FDA is denying seven-year exclusivity that orphan drugs typically get on the grounds that Bendeka shares the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

Subscribers Only

Date Filed

April 27, 2016

Law Firms

Companies

Government Agencies